Key result
Targeted antioxidants show potential therapeutic benefits in preclinical diabetic cardiomyopathy models.
Understanding the mechanisms of oxidative stress in diabetic cardiomyopathy highlights Nrf2 and metallothionein as promising therapeutic targets for future clinical translation.
Antioxidant targeting of Nrf2 and metallothionein warrants clinical investigation in diabetic cardiomyopathy; leaves open translation from preclinical models.
Diabetic cardiomyopathy as an important threat to health occurs with or without coexistence of vascular diseases. The exact mechanisms underlying the disease remain incompletely clear. Although several pathological mechanisms responsible for diabetic cardiomyopathy have been proposed, oxidative stress is widely considered as one of the major causes for the pathogenesis of the disease. Hyperglycemia-, hyperlipidemia-, hypertension- and inflammation-induced oxidative stress are major risk factors for the development of microvascular pathogenesis in the diabetic myocardium, which results in abnormal gene expression, altered signal transduction and the activation of pathways leading to programmed myocardial cell deaths. In the present article, we aim to provide an extensive review of the role of oxidative stress and anti-oxidants in diabetic cardiomyopathy based on our own works and literature information available.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2014) conducted a review in Diabetic cardiomyopathy. Antioxidants (e.g., Nrf2 activators, metallothionein) was evaluated. Oxidative stress plays a major role in the pathogenesis of diabetic cardiomyopathy, and antioxidants targeting Nrf2 and metallothionein show potential therapeutic benefits in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: